Advertisement

 

 

Impact of protease inhibitors on circulating PCSK9 levels in HIV-infected antiretroviral-naive patients from an ongoing prospective cohort.

Impact of protease inhibitors on circulating PCSK9 levels in HIV-infected antiretroviral-naive patients from an ongoing prospective cohort.
Author Information (click to view)

Boccara F, Ghislain M, Meyer L, Goujard C, May CL, Vigouroux C, Bastard JP, Fellahi S, Capeau J, Cohen A, Cariou B, ,


Boccara F, Ghislain M, Meyer L, Goujard C, May CL, Vigouroux C, Bastard JP, Fellahi S, Capeau J, Cohen A, Cariou B, , (click to view)

Boccara F, Ghislain M, Meyer L, Goujard C, May CL, Vigouroux C, Bastard JP, Fellahi S, Capeau J, Cohen A, Cariou B, ,

Advertisement

AIDS (London, England) 31(17) 2367-2376 doi 10.1097/QAD.0000000000001633

Abstract
OBJECTIVE
The study aims to assess the association between proprotein convertase subtilisin/kexin type 9 (PCSK9), a major regulator of LDL cholesterol (LDL-C) homeostasis, and HIV-related dyslipidaemia in a cohort of HIV-positive (HIV+) patients under protease inhibitors.

METHODS
Plasma PCSK9 levels were measured in 103 HIV+ patients before and after initiating protease inhibitor-based antiretroviral therapy (ART), and in 90 HIV-negative controls matched for age and sex. PCSK9 was measured by ELISA. HIV+ patients who were not virologically suppressed at follow-up or were on lipid-lowering therapy were excluded.

RESULTS
In HIV+ (median age 36 years; 77.7% men), PCSK9 levels did not increase after protease inhibitor exposure (median 14 months) (279.5 ng/ml before, 289.6 ng/ml after; P = 0.49) and were significantly elevated versus controls at all timepoints (adjusted P value before and after: <0.05). After protease inhibitor initiation, total cholesterol, LDL-C and HDL cholesterol levels increased, but LDL-C remained lower versus controls. At baseline, PCSK9 levels were positively associated with immunodeficiency and the severity of HIV disease [HIV-1 viral load (P = 0.01), CD4 T-cell count <200/μl, P = 0.002], stage C HIV disease (P = 0.0002). In protease inhibitor-treated patients, PCSK9 levels were no longer associated with HIV-related factors but with total cholesterol (P = 0.0006), LDL-C (P = 0.01), HDL cholesterol (P = 0.01), triglycerides (P = 0.05) and glycaemia (P = 0.006). CONCLUSION
PSCK9 levels are elevated in HIV+ patients. In ART-naive patients, the relationship between PCSK9 levels and infection severity suggests an effect of HIV disease. After initiating protease inhibitor-containing ART in virologically suppressed patients, PCSK9 levels were associated with dyslipidaemia similar to controls.

Submit a Comment

Your email address will not be published. Required fields are marked *

two + 20 =

[ HIDE/SHOW ]